制药业面临向最高法院提起IRA诉讼的最后期限，首批议定价格即将出台
Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices looms
生命科学资讯
生物技术与制药领域的最新动态
FDA批准Sarepta采用Elevidys进行新型免疫抑制方法研究；吉利德收购临床前TREX1项目
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
诺和诺德药物Amycretin在二期糖尿病试验中减轻体重并降低血糖
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
诺华以120亿美元收购艾维迪成为唯一竞标者
Novartis was the sole bidder in $12B deal to buy Avidity
#Avidity Biosciences#buy Avidity#chief executives#billion agreement#sole bidder
FDA的Pazdur被称为对委员行为提出问题，新代金券 (Note: Pazdur likely refers to Richard Pazdur, the Director of the FDA's Oncology Center of Excellence. Commissioners likely refers to the FDA commissioners. The title is translated to Simplified Chinese as above.)
FDA's Pazdur is said to raise questions about commissioners actions, new voucher
#commissioners actions#raise questions#FDA Pazdur#Richard Pazdur#Marty Makary
英国-美国药品定价协议可能在这周内到来，消息人士说
UK-US drug pricing deal could come as early as this week, sources say
#told Endpoints#UK-US drug#matter told#drug pricing#pricing deal
ASH25：科林尼亚首次CAR-T体内数据；利立、J&J和诺バ特斯制定Phase 3胜局
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins
#American Society#wins Late-breaking#Big pharma#Novartis spell#Late-breaking abstracts
🚀 Here is the translation: 强生公司 Tau 目标抗体Phase 2 Альцгеймер病研究失败
J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study
#fails Phase#Alzheimer study#study Johnson#early-stage disease#promising candidates
凯伦的TROP2 ADC加Keytruda在非小细胞肺癌的第一线治疗中改善了疗效
Kelun's TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer
#first-line lung#lung cancer#cancer Merck#Keytruda improves#Chinese regulatory
赛普塔支付0.5亿美元milestone给阿罗韦德；恩利维克斯报告骨关节炎数据
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data
#Clearside Biomedical#MindImmune Therapeutics#Enlivex reports#pay Arrowhead#continues type
Here is the translation: 拜奥젠与新开发商Dayra Therapeutics签订I&I协议
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeutics
#Versant Ventures’#Dayra Therapeutics#Ventures’ latest#Therapeutics Versant#Versant macrocycle
拜尔公司股票回升，下一代抗血栓药物在第三期试验中取得胜利
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
#win Bayer#high-profile failures#stock rallies#next-gen blood#blood thinner
Novo Nordisk的semaglutide在高度关注的阿尔茨海默病试验中失败了
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
Craig Crews, Mikael Dolsten raise 2M for Quarry Thera Craig Crews, Mikael Dolsten 为 Quarry Thera 增援 2,000,000 美元
Craig Crews, Mikael Dolsten raise $32M for Quarry Thera
#Mikael Dolsten#Quarry Thera#Craig Crews#Dolsten raise#Mikael
Nobel laureate Carolyn Bertozzi 将重返利立瑞董事会
Nobel laureate Carolyn Bertozzi to rejoin Lilly board
#Carolyn Bertozzi#Eli Lilly#SEC filing#Friday evening#evening SEC
Here is the translation: 马卡瑞的用户费用评论；M&A活动保持热烈；prime 编辑的新用途等等
Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and more
#Endpoints Weekly#fee comments#stays hot#prime editing#user fee
Top级Makary助手Jain-Nagpal仍在FDA中White House推迟
Top Makary aide Jain-Nagpal remains at the FDA after White House pushback
#White House#Commissioner Marty#FDA Commissioner#Marty Makary#Top Makary
阿斯利康将罕见病药物组合本土化，作为其向美国承诺的500亿美元投资的一部分。
AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the US
#announced Friday#billion pledge#onshore rare#rare disease#disease portfolio
梯瓦制药在华盛顿联邦法院对IRA药品定价法案的挑战败诉
Teva loses IRA drug pricing challenge in DC federal court
#federal court#loses IRA#IRA drug#Medicare negotiations#pharma industry
🚀 Here is the translation of the title to Simplified Chinese: 赛瑞塔公司终止Elevidys试验； Moderna部分pipeline项目被砍 Please note that pre-treatment is not explicitly translated in the title, as it is a concept rather than a specific term.
Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna
#Blue Lake#Inhibikase Therapeutics#Olema Oncology#Elevidys trial#Hansa Biopharma